Coronary/Structural Heart

St. Joseph’s Children’s Hospital First in Tampa Bay to Implant New Device That Narrows the Gap When it Comes to Transcatheter Heart Valve Repair

The innovative pre-stent standardizes the shape of the pulmonary valve opening, allowing for a higher number of patients to be candidates for transcatheter valve replacement. TAMPA, Fla., Aug. 30, 2022 /PRNewswire/ — Erin Ambrose knew the day would come. The day she would once again watch her daughter, Hailey, be wheeled into an operating […]

Medtronic announces partnership with BioIntelliSense for exclusive U.S. distribution of multi-parameter wearable for continuous remote patient monitoring from in-hospital to home

Partnership reflects commitment to patient safety; BioButton® wearable offers up to 1,440 vital signs measurements daily, monitoring patients transitioning from higher to lower acuity settings Technology complements the Medtronic Patient Monitoring business’ HealthCast™ intelligent patient manager portfolio designed for connectivity, visualization, remote patient monitoring, and now, wearables DUBLIN, Aug. 31, 2022 /PRNewswire/ […]

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

Adaptive Statistical Analysis Plan Recommended SUNNYVALE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase […]

Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients

Data show ultrafiltration for post-operative CABG patients provides a safe and effective method for managing fluid balance and reducing mortality rates MINNEAPOLIS, Aug. 31, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the publication of key clinical […]

Hello Heart Announces a Groundbreaking Feature for Managing Cholesterol, Becoming the First and Only Digital Therapeutic to Tackle Whole-Heart Health

As we approach National Cholesterol Education Month, My Cholesterol will provide millions of users with clarity on their cholesterol and triglycerides trends through personalized, gender-specific insights and coaching MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the only digital therapeutic that focuses exclusively on heart health, today announced a new cholesterol management feature, designed to […]

New Data Show Abbott’s HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients

  New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for advanced heart failure patients who don’t receive either a heart pump or heart transplant is […]

NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS

Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death 80% of Patients Achieved Guideline Directed LDL-C Levels of <55 mg/dL at Week 12 Data Presented at ESC 2022 and Simultaneously Published in Circulation THOUSAND OAKS, Calif., Aug. 29, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented new […]

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers

— Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis — –– Data Presented as an Oral Abstract at European Society of Cardiology (ESC) Congress 2022 in Barcelona and Published in EHJ Cardiovascular […]

FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial

Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaningful benefits of FARXIGA in patients with heart failure regardless of ejection fraction Heart failure is a chronic, progressive disease impacting nearly 64 million people August 27, 2022 10:36 AM Eastern […]

Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy

~30% relative risk reduction seen in symptomatic ischemic strokes in three milvexian arms compared to placebo; dose response not observed for primary study objective No fatal bleeding and no increase in symptomatic intracranial hemorrhage observed in patients treated with milvexian, even with all patients receiving 21 days of background dual […]